Akero returns with more MASH data to back PhIII drug, touts fibrosis response rate
Akero Therapeutics is back with more data for its FGF21 analog in metabolic dysfunction-associated steatohepatitis (MASH), a disease space that’s been
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
